Thursday, November 30, 2023


“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

First Postpartum Depression Drug Fast Tracked and Licensed by FDA

postpartum depression

On Aug. 4, 2023, the U.S. Food and Drug Administration (FDA) fast tracked licensure of the oral prescription medication Zurzuvae (zuranolone), manufactured by Sage Therapeutics, Inc. as a treatment for postpartum depression. Postpartum affects roughly one in seven women and typically begins after childbirth but, for some women, it can begin during later stages of […]

Search in Site

To search in site, type your keyword and hit enter